Top

Published in:

01-12-2011 | Colorectal Cancer

Survival and Quality of Life Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colonic Origin

Authors: Adrienne R. Hill, DO, Richard P. McQuellon, PhD, Gregory B. Russell, MS, Perry Shen, MD, John H. Stewart IV, MD, Edward A. Levine, MD

Published in: Annals of Surgical Oncology | Issue 13/2011

Abstract

Background

Peritoneal carcinomatosis of colonic origin (PCC) is a life-threatening diagnosis. Cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers patients the prospect of long-term survival with alleviation of symptoms.

Methods

Patients underwent HIPEC for PCC and completed questionnaires preoperatively (T1) and after surgery at 3 (T2), 6 (T3), and 12 (T4) months. Questionnaires included the Functional Assessment of Cancer Therapy—Colon (FACT-C), Brief Pain Inventory (BPI), SF-36 Medical Outcomes Study Survey (SF-36), Center for Epidemiologic Studies—Depression Scale (CES-D), and the ECOG Performance Status Rating.

Results

A total of 62 patients were assessed before surgery. Median overall survival was 18 months, with 71.3 ± 6.3% survival at 1 year. Emotional well-being (P = .0007) improved after HIPEC. Social/family well-being (P = .065) and the colon subscale (P = .061) of the FACT worsened at T2, but recovered by T3. One-third to one-half of patients reported depressive symptoms over the course of the study. Pain scores increased above BL at T2, but decreased below BL at T3 and T4.

Conclusions

Emotional well being is improved after CS + HIPEC despite complications that may affect short-term recovery. Most patients remaining in the study recover to preoperative levels of functioning between 3 and 6 months after surgery. For some, survival can be attained without major decrement in QOL at 1 year. QOL concerns must be a key component in the evaluation for patients with PCC for CS and HIPEC.

Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11:178–86.PubMedCrossRef

Tuttle TM, Zhang Y, Greeno E, Knutsen A. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2006;13:1627–32.PubMedCrossRef

Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364–7.PubMedCrossRef

Levine EA, Stewart JH, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204:943–53.PubMedCrossRef

Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer. 2000;88:2512–9.PubMedCrossRef

Witkamp AJ, deBree E, Kaag MM, Boot H, Beijnen JH, van Slooten GW, et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2001;37:979–84.PubMedCrossRef

Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Clin Oncol. 2004;85:61–7.

McQuellon RP, Russell GB, Shen P, Stewart JH 4th, Saunders W, Levine EA. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol. 2007;15:125–33.PubMedCrossRef

McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155–62.PubMedCrossRef

10.

Zubrod CG, Schneiderman M, Frei E, Brindley C, Gold GG, Shnider B, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramind. J Chronic Dis. 1960;11:7–33.CrossRef

11.

Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.PubMed

12.

Eton D, Fairclough D, Cella D, Yount S, Bonomi P, Johnson D. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003;21:1536–43.PubMedCrossRef

13.

McQuellon R, Thaler H, Cella D, Moore D. Quality of Life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a gynecologic oncology group study. Gynecol Oncol. 2006;101;296–304.PubMedCrossRef

14.

Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15:974–86.PubMed

15.

Ware JR Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey. In: Manual and Interpretation Guide. Boston: Nimrod Press, 1993.

16.

McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–63.PubMedCrossRef

17.

Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure. 1977;1:385–401.CrossRef

18.

Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197–210.PubMedCrossRef

19.

McQuellon RP, Loggie BW, Fleming RA, Russel GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (HIPEC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27:65–73.PubMedCrossRef

20.

Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic interperitoneal chemotherapy. Eur J Surg Oncol. 2005;31:53–8.PubMedCrossRef

21.

Jess P, Iversen LH, Nielsen MB, Hansen F, Laurberg S, Rasmussen P. Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study. Dis Colon Rectum. 2008;51:868–74.PubMedCrossRef

22.

Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2006;14:484–92.PubMedCrossRef

23.

McQuellon R, Gavazzi C, Piso P, Swain D, Levine E. Quality of life and nutritional assessment in peritoneal surface malignancy (PSM): recommendations for care. J Surg Oncol. 2008;98:300–5.PubMedCrossRef

24.

Wilson TR, Alexander DJ. Clinical and non-clinical factors influencing postoperative health-related quality of life in patients with colorectal cancer. Br J Surg. 2008;95:1408–15.PubMedCrossRef

25.

Ulander K, Jeppsson B, Grahn G. Quality of life and independence in activities of daily living preoperatively and at follow-up in patients with colorectal cancer. Support Care Cancer. 1997;5:402–9.PubMedCrossRef

26.

Anthony T, Long J, Hynan LS, Sarosi GA Jr, Nwariaku F, Huth J, et al. Surgical complications exert a lasting effect on disease-specific health-related quality of life for patients with colorectal cancer. Surgery. 2003;134:119–25.PubMedCrossRef

27.

Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baton O, et al Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518–21.PubMedCrossRef

Title: Survival and Quality of Life Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colonic Origin
Authors: Adrienne R. Hill, DO
Richard P. McQuellon, PhD
Gregory B. Russell, MS
Perry Shen, MD
John H. Stewart IV, MD
Edward A. Levine, MD
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 13/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-1793-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Survival and Quality of Life Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colonic Origin

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 13/2011

Limitations of the ACS NSQIP in Thyroid Surgery

Risk and Predictors of Malignancy in Women with Endometrial Polyps

Modified Pleural Tenting for Prevention of Anastomotic Leak After Ivor Lewis Esophagogastrectomy

Oral Vitamin B12 Replacement: An Effective Treatment for Vitamin B12 Deficiency After Total Gastrectomy in Gastric Cancer Patients

Medical and Surgical Risks in Thyroid Surgery: Lessons from the NSQIP

Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site